[go: up one dir, main page]

AR046146A1 - Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso - Google Patents

Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso

Info

Publication number
AR046146A1
AR046146A1 ARP040103859A ARP040103859A AR046146A1 AR 046146 A1 AR046146 A1 AR 046146A1 AR P040103859 A ARP040103859 A AR P040103859A AR P040103859 A ARP040103859 A AR P040103859A AR 046146 A1 AR046146 A1 AR 046146A1
Authority
AR
Argentina
Prior art keywords
active agent
copolymer
spraying
pharmaceutical formulations
water vehicle
Prior art date
Application number
ARP040103859A
Other languages
English (en)
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AR046146A1 publication Critical patent/AR046146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan formulaciones transdérmicas para pulverización que contienen un agente activo desde el punto de vista farmacéutico y métodos para la administración de las mismas. Las formulaciones comprenden el agente activo desde el punto de vista farmacéutico, un copolímero de VP/VA y un vehículo no acuoso. Las formulaciones comprenden adicionalmente un agente contra la nucleación para prevenir la recristalización del agente activo desde el punto de vista farmacéutico y un intensificador de la penetración para incrementar el índice de administración del fármaco a través de la piel. Luego de la aplicación a la piel, las presentes formulaciones se secan para proporcionar una película en el sitio de tratamiento.
ARP040103859A 2003-10-23 2004-10-22 Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso AR046146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1122MU2003 2003-10-23

Publications (1)

Publication Number Publication Date
AR046146A1 true AR046146A1 (es) 2005-11-23

Family

ID=34531861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103859A AR046146A1 (es) 2003-10-23 2004-10-22 Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso

Country Status (23)

Country Link
US (1) US20070219171A1 (es)
EP (1) EP1686969A1 (es)
JP (1) JP2007509122A (es)
KR (1) KR20070000397A (es)
CN (1) CN100431531C (es)
AP (1) AP2006003628A0 (es)
AR (1) AR046146A1 (es)
AU (1) AU2004285335B2 (es)
BR (1) BRPI0415725A (es)
CA (1) CA2543245A1 (es)
IL (1) IL175094A0 (es)
MA (1) MA28167A1 (es)
MX (1) MXPA06004460A (es)
NO (1) NO20062234L (es)
NZ (1) NZ547376A (es)
PA (1) PA8615501A1 (es)
PE (1) PE20050443A1 (es)
RU (1) RU2006117527A (es)
SM (1) SM200400022B (es)
SV (1) SV2006001916A (es)
TW (1) TW200524635A (es)
WO (1) WO2005041943A1 (es)
ZA (1) ZA200604036B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518769D0 (en) * 2005-09-14 2005-10-19 Medpharm Ltd Topical formulations
CA2719512A1 (en) * 2010-11-01 2012-05-01 Stiefel Research Australia Pty Ltd Polymeric topical compositions
CN102018671B (zh) * 2011-01-05 2012-07-25 浙江大学 一种雌二醇透皮喷雾剂及其制备方法
US20150065449A1 (en) * 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
GB201200062D0 (en) * 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
TWI516281B (zh) * 2014-07-16 2016-01-11 健維生技有限公司 改良之睪固酮製劑製法及所得之睪固酮製劑
PL3380080T3 (pl) * 2015-11-23 2022-03-07 Nortic Holdings Inc. Tworzący film spray do stosowania miejscowego
WO2019140087A1 (en) * 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
AU2019299538B2 (en) * 2018-07-05 2025-05-08 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN112206222A (zh) * 2018-11-09 2021-01-12 北京德默高科医药技术有限公司 含有布洛芬结构类似物的多层经皮给药系统
CN115154661A (zh) * 2022-07-29 2022-10-11 广州莱度品牌管理有限公司 一种仿生角质膜的制备方法
CN118593475B (zh) * 2024-06-06 2025-07-25 暨南大学 用于治疗帕金森病的组合物、鼻喷雾剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625150B2 (en) * 1987-05-27 1992-07-02 Kurt Burghart Transdermal therapeutically effective pharmaceutical dressing and device for applying it
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
FR2739031B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
PT1150661E (pt) * 1999-02-05 2004-02-27 Cipla Ltd Produto para pulverizacao para aplicacao topica
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US6274167B1 (en) * 2000-09-14 2001-08-14 Vincent Margiotta Topical anesthetic patch
US6528040B1 (en) * 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
DE10211832A1 (de) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion

Also Published As

Publication number Publication date
SM200400022A (it) 2005-08-24
IL175094A0 (en) 2006-08-20
RU2006117527A (ru) 2007-12-10
NO20062234L (no) 2006-06-30
CA2543245A1 (en) 2005-05-12
SM200400022B (it) 2005-08-24
JP2007509122A (ja) 2007-04-12
PE20050443A1 (es) 2005-06-14
MXPA06004460A (es) 2006-06-27
AP2006003628A0 (en) 2006-06-30
WO2005041943A1 (en) 2005-05-12
KR20070000397A (ko) 2007-01-02
PA8615501A1 (es) 2005-10-25
BRPI0415725A (pt) 2006-12-19
SV2006001916A (es) 2006-03-16
MA28167A1 (fr) 2006-09-01
CN100431531C (zh) 2008-11-12
ZA200604036B (en) 2007-09-26
EP1686969A1 (en) 2006-08-09
HK1098351A1 (zh) 2007-07-20
TW200524635A (en) 2005-08-01
CN1897927A (zh) 2007-01-17
AU2004285335A1 (en) 2005-05-12
AU2004285335B2 (en) 2011-02-10
US20070219171A1 (en) 2007-09-20
NZ547376A (en) 2009-07-31

Similar Documents

Publication Publication Date Title
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
MX387061B (es) Formulación farmacéutica en aerosol formadora de película polimérica que comprende un agente activo y povidona como agente inhibidor de la precipitación de cristales de fármaco/polímero formador de película hidrofílico.
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
BR0312007A (pt) Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
BRPI0412211A (pt) composições de liberação controlada
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
AR062167A1 (es) Sistema de administracion gastrorretentivo
NZ605469A (en) Nalbuphine-based formulations and uses thereof
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
DK1311249T3 (da) Sæt af transdermale terapeutiske systemer
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2007022090A3 (en) Topical delivery with a carrier fluid
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
ZA202309969B (en) Laquinimod formulation for ocular use
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
DOP2004001018A (es) Transdermal pharmaceutical formulations
UY28579A1 (es) Formulaciones farmacéuticas transdermicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure